Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition.
Journal of Clinical Investigation.
Times cited: 217
Tumor budding correlates with the protumor immune microenvironment and is an independent prognostic factor for recurrence of stage i lung adenocarcinoma.
Times cited: 25
Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity.
Science Translational Medicine.
Times cited: 179